2-{2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid
| Title | Journal |
|---|---|
| Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. | Toxicology in vitro : an international journal published in association with BIBRA 20180401 |
| Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. | Chemical research in toxicology 20170515 |
| Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. | Toxicology letters 20150702 |
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | Toxicological sciences : an official journal of the Society of Toxicology 20140101 |
| [New drugs for small animals in 2011]. | Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere 20121017 |
| Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. | Retina (Philadelphia, Pa.) 20121001 |
| In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. | Chemical research in toxicology 20120820 |
| Acute corneal melt associated with topical bromfenac use. | Eye & contact lens 20120701 |
| Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. | Retina (Philadelphia, Pa.) 20120301 |
| Predicting psychopharmacological drug effects on actual driving performance (SDLP) from psychometric tests measuring driving-related skills. | Psychopharmacology 20120301 |
| Ocular medicines in children: the regulatory situation related to clinical research. | BMC pediatrics 20120101 |
| Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction. | Clinical ophthalmology (Auckland, N.Z.) 20120101 |
| A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. | PloS one 20120101 |
| Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study. | Clinical ophthalmology (Auckland, N.Z.) 20120101 |
| Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site. | Clinical ophthalmology (Auckland, N.Z.) 20120101 |
| Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients. | Journal of ophthalmic inflammation and infection 20111201 |
| A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. | Current medical research and opinion 20111201 |
| Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. | Advances in therapy 20111201 |
| Inflammation after phakic implants. | Ophthalmology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. | Ophthalmology 20111101 |
| The kinetics of herpes virus on the ocular surface and suppression of its reactivation. | Cornea 20111001 |
| NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. | Laboratory investigation; a journal of technical methods and pathology 20110901 |
| Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. | Current medical research and opinion 20110901 |
| Cataract and diabetic retinopathy. | Community eye health 20110901 |
| Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110401 |
| Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110201 |
| Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Four cases of corneal perforation in patients with chronic graft-versus-host disease. | Molecular vision 20110101 |
| Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Treating ocular surface disease: new agents in development. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Erratum: corrigendum. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Different cellular effects of four anti-inflammatory eye drops on human corneal epithelial cells: independent in active components. | Molecular vision 20110101 |
| Combination therapies in ophthalmology: implications for intravitreal delivery. | Journal of ophthalmic & vision research 20110101 |
| Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? | World journal of gastroenterology 20101207 |
| Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. | Acta ophthalmologica 20101201 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. | Advances in therapy 20101001 |
| Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells. | Biocontrol science 20100901 |
| NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. | Retina (Philadelphia, Pa.) 20100201 |
| Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data. | BMC bioinformatics 20100101 |
| Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. | Clinical ophthalmology (Auckland, N.Z.) 20100101 |
| Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. | Clinical ophthalmology (Auckland, N.Z.) 20100101 |
| Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. | BMC musculoskeletal disorders 20100101 |
| Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. | Clinical ophthalmology (Auckland, N.Z.) 20100101 |
| Ocular pharmacokinetics of 0.45% ketorolac tromethamine. | Clinical ophthalmology (Auckland, N.Z.) 20100101 |
| Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. | Drug metabolism and disposition: the biological fate of chemicals 20091201 |
| Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. | Expert opinion on pharmacotherapy 20091001 |
| Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress. | Archives of biochemistry and biophysics 20091001 |
| Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. | Retina (Philadelphia, Pa.) 20091001 |
| Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification. | Journal of cataract and refractive surgery 20090901 |
| Concentration and dosing of ketorolac versus bromfenac. | Journal of cataract and refractive surgery 20090701 |
| Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20090601 |
| Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. | Advances in therapy 20090601 |
| Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. | Acta ophthalmologica 20090501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. | Current eye research 20090301 |
| Psychoactive medication and traffic safety. | International journal of environmental research and public health 20090301 |
| Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK. | Journal of refractive surgery (Thorofare, N.J. : 1995) 20090201 |
| Randomized controlled trial design in rheumatoid arthritis: the past decade. | Arthritis research & therapy 20090101 |
| Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. | BMC clinical pharmacology 20090101 |
| Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. | Clinical ophthalmology (Auckland, N.Z.) 20090101 |
| Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. | Retina (Philadelphia, Pa.) 20090101 |
| Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | PloS one 20090101 |
| Etiology and treatment of the inflammatory causes of cystoid macular edema. | Journal of inflammation research 20090101 |
| Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081201 |
| Off-label promotion, on-target sales. | PLoS medicine 20081001 |
| Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. | Journal of cataract and refractive surgery 20080901 |
| Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. | Journal of cataract and refractive surgery 20080801 |
| 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20080801 |
| Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. | Clinical & experimental ophthalmology 20080801 |
| Topical ocular delivery of NSAIDs. | The AAPS journal 20080601 |
| Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. | Clinical ophthalmology (Auckland, N.Z.) 20080601 |
| Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. | Cell biology and toxicology 20080101 |
| The systemic safety of bromfenac ophthalmic solution 0.09%. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20071201 |
| A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. | Clinical ophthalmology (Auckland, N.Z.) 20071201 |
| Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. | Clinical ophthalmology (Auckland, N.Z.) 20071201 |
| Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. | Ophthalmology 20070901 |
| In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. | Journal of cataract and refractive surgery 20070901 |
| Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. | Journal of cataract and refractive surgery 20070901 |
| Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070201 |
| Effect of ophthalmic solution components on acrylic intraocular lenses. | Journal of cataract and refractive surgery 20070101 |
| Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20070101 |
| Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). | Advances in therapy 20070101 |
| Misuse and abuse of topically applied nonsteroidal anti-inflammatory drugs. | Cornea 20061201 |
| Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. | Cornea 20061201 |
| Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. | Clinical therapeutics 20060801 |
| Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. | The Clinical journal of pain 20060601 |
| Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. | Current medical research and opinion 20060601 |
| A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. | Pharmacoepidemiology and drug safety 20060401 |
| Hy's law: predicting serious hepatotoxicity. | Pharmacoepidemiology and drug safety 20060401 |
| How can 'Hy's law' help the clinician? | Pharmacoepidemiology and drug safety 20060401 |
| Ximelagatran: direct thrombin inhibitor. | Vascular health and risk management 20060301 |
| Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. | Cornea 20060201 |
| Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. | Current medical research and opinion 20060201 |
| Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. | International ophthalmology clinics 20060101 |
| New drugs and dosage forms. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050501 |
| Do preclinical testing strategies help predict human hepatotoxic potentials? | Toxicologic pathology 20050101 |
| Drug-induced liver disease in 2003. | Current opinion in gastroenterology 20040501 |
| Drug-induced liver injury. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301 |
| Analgesics for acute pain: Meeting the United States Food and Drug Administration's requirements for proof of efficacy. | The Clinical journal of pain 20040101 |
| Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. | Japanese journal of ophthalmology 20040101 |
| Effects of nonsteroidal anti-inflammatory drugs on experimental allergic conjunctivitis in Guinea pigs. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20031201 |
| Drug-induced hepatotoxicity. | The New England journal of medicine 20030731 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030601 |
| Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost. | The British journal of ophthalmology 20030301 |
| Effects of topical corticosteroids and nonsteroidal anti-inflammatory drugs on prostaglandin e2-induced aqueous flare elevation in pigmented rabbits. | Ophthalmic research 20030101 |
| Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. | Seminars in liver disease 20020101 |
| Acute liver failure. | Current opinion in gastroenterology 20010501 |
| Serious liver injury. Leading reason for drug removals, restrictions. | FDA consumer 20010101 |
| Structure toxicity relationships--how useful are they in predicting toxicities of new drugs? | Advances in experimental medicine and biology 20010101 |
| Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. | The American journal of gastroenterology 19990801 |